Biochemist was the first to register 12 domestic antibiotics

JSC Biochemik, which is the leader in the production of antibiotics in the Russian Federation, continues its revolutionary breakthrough.

The company received a registration certificate for the production of generic Doripenem, the first in the country. This is a clear indicator of the innovative development of the plant, which registered ten more antibiotics of various groups and forms in the previous nine months alone. The company does not intend to stop there. In 2019, 17 antibiotics will receive registration documents.

Basically, all registered antimicrobial drugs have a wide spectrum of action. For example, Levofloxacin, Moxifloxacin, which is included in the list of VED, Azithromycin, Linezolid are used for infections of the upper and lower respiratory tract, infections of the skin and soft tissues, urinary tract and kidneys, and others. The list of registered drugs also includes an anti–tuberculosis antibiotic, Capriomycin (powder for injection preparation). It is used for tuberculosis of the lungs, for ineffectiveness or intolerance of first-line anti-tuberculosis drugs, as well as for resistance to them. These are important medicines for any country, which is confirmed by statistics.

Today, tuberculosis ranks ninth among the causes of death in the world's population. Significantly more people die from it in the world than from HIV and AIDS combined (for example, the 2016 figure is one million 300 thousand deaths). The total number of cases exceeded ten million. According to WHO estimates, tuberculosis is one of the most dangerous infectious diseases in the world, along with AIDS and hepatitis.

Commenting on the breakthrough of Biochemist, practitioners emphasize the importance of certain medical aspects.:

Zhuravleva Marina Vladimirovna, MD, Professor, Deputy Director of the Center for Clinical Pharmacology of the Scientific Center for Expertise of Medical Devices of the Ministry of Health of the Russian Federation

"Antibiotics are drugs that have allowed humanity to save 30 years of life. Our task is to rationally apply this class of medicines and combat the spreading antibiotic resistance. The most important groups among antibiotics are carbapenems, cephallosporins, and macrolides. Thus, carbapenems not only help reduce the risk of death in patients with nosocomial infections, but also optimize treatment and reduce hospital stay. The creation of effective Russian-made antimicrobials that are therapeutically equivalent to their foreign counterparts is an urgent task for domestic pharmaceutical manufacturers. A lot of work on the development and production of antimicrobial drugs is carried out at Biochemistry, a plant operating in accordance with GMP standards. We hope that the medicines he produces that meet the criteria of efficacy and safety will ensure the availability of high-quality medicines for patients."

Evdokimova Anna Grigorievna, MD, Honored Doctor of the Russian Federation, Professor of the Department of Internal Diseases, Faculty of Dentistry, Moscow State Medical University named after A.I. Evdokimov

 "Given the increasing resistance of pathogenic microorganisms to modern antibiotics, on the one hand, and the high prevalence of nosocomial infections (up to 15% in our country), on the other hand, clinicians have a high need to use nosologically correct, effective and least toxic drugs with persistent bactericidal action. One of the most sought-after classes of antibiotics is carbapenems, which are active against most Gram-positive and Gram-negative aerobic and anaerobic bacteria, including multidrug-resistant ones. Due to its pharmacological profile, efficacy and safety, Doripenem, used for the treatment of nosocomial pneumonia, complicated intra-abdominal infections, and urinary tract infections, occupies an important place among the drugs in this group. The use of this antibiotic is sometimes limited due to the high cost of treatment. We hope that the development of domestic Doripenem, which will be handled by JSC Biochemik, will help make effective therapy more accessible and will help increase the life expectancy of the population of our country."

Zherebker Evgeniya Mikhailovna, Candidate of Medical Sciences, BPSC RAS

"Of course, the creation of fully Russian antibiotics is an extremely important step towards increasing the availability of the necessary tools to combat infectious diseases. It is important to remember not only about the potential of antimicrobial activity, but also about the minimum range of side effects. Macrolides are considered to be the safest antibacterial drugs. A distinctive feature of these drugs is that this group practically does not cause allergies, as, for example, it is often noted after taking antibiotics of the penicillin group or cephalosporins. Among the drugs in this group, it is worth highlighting Azithromycin. Combined with high safety, even with prolonged use, including in pediatric and geriatric practice, it has pharmacological activity that allows it to be considered both as an antibacterial agent in the treatment of intracellular infectious pathogens, and as an immunomodulatory drug. The production of the new Azithromycin certainly confirms the willingness of JSC Biochemik to provide the medical community with the most in-demand, affordable and safe medicines."

In early April, Moscow hosted the XI Annual All-Russian Congress with International participation "Infectious Diseases in the Modern World: evolution, current and future Threats." The event aroused wide interest among scientists and practitioners. The congress highlighted the concern of doctors about the fact that 79% of substances for the production of antimicrobials in Russia are imported from China, India, Korea and Europe, and there are high risks of a shortage of raw materials in our country, as well as the danger of an increase in the cost of medicines.

That is why Biochemik's import substitution initiatives were evaluated at the congress as unique and at the same time meeting all new standards of the global pharmaceutical industry.

The innovative projects implemented at Biochemistry ensure the fulfillment of the strategy of the President of the Russian Federation, Vladimir Putin, on import substitution and increasing Russia's export potential.